KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat.

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

Tempus AI is expanding its partnership with Verastem Oncology to develop a companion diagnostic (CDx) for the latter’s ...

Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

KRAS and NRAS are members of the RAS family of genes, which encode proteins that regulate cell growth and division through signaling pathways. Mutations in these genes disrupt normal signaling, ...

CUHK researchers say drug D3S-001 can treat non-small cell lung, colorectal and pancreatic cancers triggered by gene mutation ...

Revolution Medicines is conducting phase 3 trials for daraxonrasib, targeting active KRAS mutations, with promising results in preclinical and clinical studies. RAS(ON) therapies aim to address ...

Silexion’s new groundbreaking study explores the potential impact of its next generation RNAI therapeutic candidate beyond pancreatic cancer aiming to address critical unmet needs in additional ...

“Today’s approval of AVMAPKI FAKZYNJA CO-PACK for patients with KRAS-mutated recurrent low-grade serous ovarian cancer represents not only the first-ever FDA-approved treatment specifically ...

On May 8, the Food and Drug Administration granted accelerated approval to the combination of avutometinib and defactinib for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer ...